JP2024038256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038256A5 JP2024038256A5 JP2024000257A JP2024000257A JP2024038256A5 JP 2024038256 A5 JP2024038256 A5 JP 2024038256A5 JP 2024000257 A JP2024000257 A JP 2024000257A JP 2024000257 A JP2024000257 A JP 2024000257A JP 2024038256 A5 JP2024038256 A5 JP 2024038256A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mammal
- antigen receptor
- cell
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521011P | 2017-06-16 | 2017-06-16 | |
| US62/521,011 | 2017-06-16 | ||
| US201862618399P | 2018-01-17 | 2018-01-17 | |
| US62/618,399 | 2018-01-17 | ||
| PCT/US2018/037874 WO2018232318A1 (en) | 2017-06-16 | 2018-06-15 | Materials and methods for increasing immune responses |
| JP2019569301A JP7416629B2 (ja) | 2017-06-16 | 2018-06-15 | 免疫応答を増強するための物質および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569301A Division JP7416629B2 (ja) | 2017-06-16 | 2018-06-15 | 免疫応答を増強するための物質および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024038256A JP2024038256A (ja) | 2024-03-19 |
| JP2024038256A5 true JP2024038256A5 (https=) | 2024-06-24 |
Family
ID=64660538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569301A Active JP7416629B2 (ja) | 2017-06-16 | 2018-06-15 | 免疫応答を増強するための物質および方法 |
| JP2024000257A Ceased JP2024038256A (ja) | 2017-06-16 | 2024-01-04 | 免疫応答を増強するための物質および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569301A Active JP7416629B2 (ja) | 2017-06-16 | 2018-06-15 | 免疫応答を増強するための物質および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200171170A1 (https=) |
| EP (1) | EP3638262A4 (https=) |
| JP (2) | JP7416629B2 (https=) |
| CN (1) | CN110996974A (https=) |
| AU (2) | AU2018283319B2 (https=) |
| CA (1) | CA3067226A1 (https=) |
| MX (1) | MX2019015183A (https=) |
| WO (1) | WO2018232318A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| WO2024238903A1 (en) * | 2023-05-17 | 2024-11-21 | Mayo Foundation For Medical Education And Research | Materials and methods for increasing immune responses within a mammal |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040258688A1 (en) * | 1995-01-31 | 2004-12-23 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
| US6667175B1 (en) | 1999-06-15 | 2003-12-23 | The Trustees Of Columbia University | Generation of antigen specific T suppressor cells for treatment of rejection |
| US7803382B2 (en) | 2001-05-04 | 2010-09-28 | Ludwig Institute For Cancer Research Ltd. | Method for inducing immune response to NY-CO-58 |
| US7811816B2 (en) * | 2001-05-15 | 2010-10-12 | Ortho-Mcneil Pharmaeutical, Inc. | Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell |
| US20030049253A1 (en) * | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| CN1720326A (zh) | 2002-10-01 | 2006-01-11 | 株式会社载体研究所 | 通过抑制tap活性增强mhcⅰ类分子对外来表位的展示的方法 |
| PL1897548T5 (pl) * | 2003-02-28 | 2025-03-17 | The Johns Hopkins University | Regulacja komórek T |
| US20050238626A1 (en) * | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
| EP2494038B1 (en) * | 2009-10-27 | 2019-06-26 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| US9511151B2 (en) * | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US20120141537A1 (en) * | 2010-11-18 | 2012-06-07 | Pease Larry R | Enhancing t cell activation using altered mhc-peptide ligands |
| CN107858333B (zh) | 2011-10-28 | 2022-05-27 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| DK4074735T3 (da) | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| EP4286511A3 (en) * | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| SG11201803419PA (en) * | 2015-10-30 | 2018-05-30 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
| WO2018175476A1 (en) * | 2017-03-20 | 2018-09-27 | Baylor College Of Medicine | Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells |
-
2018
- 2018-06-15 EP EP18817728.1A patent/EP3638262A4/en active Pending
- 2018-06-15 MX MX2019015183A patent/MX2019015183A/es unknown
- 2018-06-15 US US16/623,268 patent/US20200171170A1/en active Pending
- 2018-06-15 JP JP2019569301A patent/JP7416629B2/ja active Active
- 2018-06-15 WO PCT/US2018/037874 patent/WO2018232318A1/en not_active Ceased
- 2018-06-15 CN CN201880052389.0A patent/CN110996974A/zh active Pending
- 2018-06-15 CA CA3067226A patent/CA3067226A1/en active Pending
- 2018-06-15 AU AU2018283319A patent/AU2018283319B2/en active Active
-
2024
- 2024-01-04 JP JP2024000257A patent/JP2024038256A/ja not_active Ceased
- 2024-01-17 AU AU2024200316A patent/AU2024200316A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038256A5 (https=) | ||
| Martin et al. | TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice | |
| Klenerman et al. | Tracking T cells with tetramers: new tales from new tools | |
| ES2394180T3 (es) | Receptor de células T de alta afinidad y uso del mismo | |
| Tirapu et al. | Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens | |
| Nilsson et al. | HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA/MVA vaccinees: a phase I randomized trial | |
| KR20140019304A (ko) | 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신 | |
| MX2020010421A (es) | Combinaciones de composición de vacunas inductoras de células t y usos de las mismas. | |
| JP2006523224A5 (https=) | ||
| Chakraborty et al. | Ongoing clinical trials of vaccines to fight against COVID-19 pandemic | |
| ES2529257T3 (es) | Vacuna basada en células B cargadas con el ligando de células T asesinas naturales y antígeno | |
| Racine et al. | Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses | |
| Nchinda et al. | Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells | |
| Flaxman et al. | Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse | |
| JP2026063215A5 (https=) | ||
| Perdiguero et al. | Heterologous combination of VSV-GP and NYVAC vectors expressing HIV-1 trimeric gp145 Env as vaccination strategy to induce balanced B and T cell immune responses | |
| JP2024038256A (ja) | 免疫応答を増強するための物質および方法 | |
| JP2023512631A5 (https=) | ||
| JP2023515806A5 (https=) | ||
| Walker et al. | Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine | |
| Ada | Twenty years into the saga of MHC‐restriction | |
| Hu et al. | Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu | |
| Geng et al. | Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells | |
| Penaloza-MacMaster et al. | Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens | |
| Bhattacharyya et al. | T regulatory cells are critical for the maintenance, anamnestic expansion and protection elicited by vaccine‐induced CD8 T cells |